Related Experiment Videos
A rat EEG model for evaluating contrast media neurotoxicity.
M D Adams1, R M Hopkins, J A Ferrendelli
1Diagnostic Products R & D, Mallinckrodt, Inc., Hazelwood, MO 63042.
Investigative Radiology
|September 1, 1988
Summary
X-ray contrast media administered intracisternally can cause neurotoxicity in rats. Meglumine iothalamate and metrizamide showed significant electroencephalographic (EEG) abnormalities and mortality, while ioversol caused milder effects.
Area of Science:
- Neuroscience
- Radiology
- Toxicology
Background:
- X-ray contrast media are essential in medical imaging.
- Assessing the neurotoxicity of these agents is crucial for patient safety.
- Intracisternal administration in animal models provides a direct route to evaluate central nervous system effects.
Purpose of the Study:
- To evaluate the electroencephalographic (EEG) effects and neurotoxicity of intracisternally administered x-ray contrast media in rats.
- To compare the neurotoxic potential of meglumine iothalamate (IOT), metrizamide (MET), iogulamide (IOG), and ioversol (IOV).
Main Methods:
- Rats were anesthetized and artificially ventilated.
- Electrodes were placed to record EEG, and arterial blood pressure (BP) was monitored.
- Contrast agents were injected via the cisterna magna at varying doses (30-240 mgI/kg).
- EEG, BP, blood gases, and pH were monitored post-injection.
Main Results:
- Normal saline control caused no significant changes.
- Meglumine iothalamate (30 mgI/kg) induced epileptogenic activity and death in 75% of animals.
- Metrizamide showed minimal effects at 30 mgI/kg but caused severe EEG changes and 33% mortality at higher doses.
- Ioversol produced mild to moderate EEG abnormalities at 120 and 240 mgI/kg.
Conclusions:
- Intracisternal administration of certain x-ray contrast media can induce significant neurotoxicity in rats.
- Meglumine iothalamate and metrizamide exhibit considerable epileptogenic potential and lethality.
- Ioversol appears to have a lower neurotoxic profile compared to IOT and MET at the tested doses.